TELA Bio Inc

For the period ended Dec 31, 2023. Filed Mar 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 22, 2024

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)


· · Year ended December 31,
· 2023 · · 2022 · 2021
Revenue	$58,453	$41,418	$29,463
Cost of revenue (excluding amortization of intangible assets)	17,961	13,570	10,346
Amortization of intangible assets	380	804	304
Gross profit	40,112	27,044	18,813
Operating expenses:
Sales and marketing	59,681	43,252	29,062
General and administrative	14,887	13,862	12,459
Research and development	9,619	8,937	6,743
Total operating expenses	84,187	66,051	48,264
Loss from operations	(44,075)	(39,007)	(29,451)
Other expense:
Interest expense	(5,223)	(4,051)	(3,597)
Loss on extinguishment of debt	—	(1,228)	—
Other income (expense)	2,634	(10)	(228)
Total other expense	(2,589)	(5,289)	(3,825)
Net loss	$(46,664)	$(44,296)	$(33,276)
Net loss per common share, basic and diluted	$(2.04)	$(2.72)	$(2.30)
Weighted average common shares outstanding, basic and diluted	22,868,663	16,267,678	14,473,213
Comprehensive loss:
Net loss	$(46,664)	$(44,296)	$(33,276)
Foreign currency translation adjustment	(59)	202	19
Comprehensive loss	$(46,723)	$(44,094)	$(33,257)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.